Literature DB >> 1336348

Comparative study of penetration of lomefloxacin and ceftriaxone into transudative and exudative pleural effusion.

M Kimura1, T Matsushima, J Nakamura, Y Kobashi.   

Abstract

We investigated the transpleural penetration of lomefloxacin (LFLX) and ceftriaxone (CTRX). LFLX (200 mg) was administered orally to three patients with transudative fluid and four with exudative fluid, and 2 g of CTRX was administered by drip infusion to four patients with transudative fluid and three with exudative fluid. For both groups that received LFLX and CTRX, blood samples were drawn at time zero and 1, 2, and 6 h after drug administration. Thoracocentesis of each group was performed at 6 h after drug administration. The mean ratios of concentrations in pleural fluid/maximum concentrations in serum (P/S max) of LFLX were 66% in patients with transudative fluid and 69% in patients with exudative fluid. The mean ratios of P/S max of CTRX were 9.1% in patients with transudative fluid and 13.5% in patients with exudative fluid. The P/S max ratios for the penetration of LFLX were five to six times higher than those for CTRX. In addition, there was less differentiation in concentrations of LFLX in pleural fluid between the transudative and exudative effusions than there was in the concentrations of CTRX.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336348      PMCID: PMC245543          DOI: 10.1128/AAC.36.12.2774

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil.

Authors:  R Dumont; F Guetat; J M Andrews; E Sultan; B Lenfant
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

2.  High-performance liquid chromatographic method for determination of ciprofloxacin in biological fluids.

Authors:  F Jehl; C Gallion; J Debs; J M Brogard; H Monteil; R Minck
Journal:  J Chromatogr       Date:  1985-05-03

3.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

4.  Pleural fluid levels of cefoxitin in patients with renal impairment.

Authors:  M Barrueco; M J Otero; M J Garcia; J M Lanao; A Dominguez-Gil
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1986-09

5.  Penetration of aminoglycosides in uninfected pleural exudates and in pleural empyemas.

Authors:  J P Thys; P Vanderhoeft; A Herchuelz; P Bergmann; E Yourassowsky
Journal:  Chest       Date:  1988-03       Impact factor: 9.410

6.  Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin.

Authors:  R Reiner; U Weiss; U Brombacher; P Lanz; M Montavon; A Furlenmeier; P Angehrn; P J Probst
Journal:  J Antibiot (Tokyo)       Date:  1980-07       Impact factor: 2.649

7.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

8.  Penetration of ciprofloxacin into human pleural fluid.

Authors:  F Jacobs; M Marchal; P de Francquen; J P Kains; D Gangji; J P Thys
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

9.  Pleural penetration of ciprofloxacin in patients with empyema thoracis.

Authors:  A Morgenroth; H P Pfeuffer; R Seelmann; H Schweisfurth
Journal:  Chest       Date:  1991-08       Impact factor: 9.410

10.  Penetration of ceftriaxone into human pleural fluid.

Authors:  G Benoni; E Arosio; L Cuzzolin; B Vaona; M G Raimondi; A Lechi
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

  10 in total
  2 in total

Review 1.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.